European Union - English - EMA (European Medicines Agency)

actavis group ptc ehf - reteplase - myocardial infarction - antithrombotic agents - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - reteplase - powder and solvent for solution for injection - 10unit

Singapore - English - HSA (Health Sciences Authority)

drug houses of australia private limited - reteplase - injection, powder, for solution - 10 u/vial

European Union - English - EMA (European Medicines Agency)

roche registration ltd. - reteplase - myocardial infarction - antithrombotic agents - thrombolytic therapy of acute myocardial infarction

Canada - English - Health Canada

ekr therapeutics inc - reteplase - powder for solution - 10.4unit - reteplase 10.4unit - thrombolytic agents